
Recombinant Activated Factor VII Is Safe in Patients With Hemophilia A Experiencing Breakthrough Bleeding
Recombinant activated factor VII (rFVIIa) is a safe and effective therapy for treating breakthrough bleeds (BTBs) in patients with hemophilia A, according to a study published in Haemophilia. Although emicizumab is an effective therapy for preventing bleeding, many patients still experience BTBs. Activated prothrombin complex concentrate (aPCC) is used for managing hemophilia-associated bleeding but is…